Measurement of hyperphosphorylated tau (P-tau) allows for differentiation of AD from other dementias with 85% accuracy, while the combined measurement of tau and Aβ1-42 can predict disease progression with 95% sensitivity and 87% specificity [14]. This evidence concerns the gene MAPT and dementia.